Health and Healthcare
Dendreon Shares Losing House Committee Hope (DNDN)
Published:
Last Updated:
CNBC’s Mike Huckman just announced what is going to be a disappointment for Dendreon (NASDAQ: DNDN) holders, and that may be an understatement. The House Committee will not be forcing any action or pressing the FDA over Dendreon’s PROVENGE until FDA makes a final decision, and that could be one to three years away. There had been hopes that the committee would uncover conflicts of interest that have been alleged by many hopeful patients and investors alike. That doesn’t look to be in the realm of possibilities now.
As a reminder, there is still hope that the EU might actually save it when the FDA wouldn’t.
Dendreon shares are now down over 7% to $5.37, and its 52-week trading range is $3.57 to $25.25.
Jon C. Ogg
February 13, 2008
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
